Keyword: Eli Lilly

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

The next courtroom showdown in the battle over drug prices in TV ads is set for Jan. 13 with Merck, Eli Lilly, Amgen and ANA versus HHS.

Eli Lilly and Boehringer Ingelheim failed to persuade an FDA expert panel that their SGLT2 med, Jardiance, could be repurposed for Type 1 diabetes.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.

Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.

Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.

While forthcoming migraine meds from Eli Lilly, Allergan and Biohaven do beat placebo, they're not much better than existing triptan drugs, ICER says.

Lilly and BI have taken the leading position with Jardiance, and now the partners are changing their 2011 alliance agreement to focus on the drug.

Cosentyx has been battling it out with Taltz in psoriatic arthritis. But Lilly’s drug has a big win under its belt that Novartis can't tout.

Lilly is facing off against new competition and dealing with lower pricing in the U.S., but key drug classes are continuing to expand, its CEO said.